Table 3.

Study schedule

Trial period	Screening/Randomization ± Start of Sacubitril/Valsartan/Lifestyle intervention	Intervention		Discontinuation of Sacubitril/Valsartan/Lifestyle Intervention	Follow up	Premature treatment discontinuation
Visit number/title	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Discontinuation visit
Schedules days/week/month	day 1	Day 14	Day 28	Week 16 (month 4)	Week 28 (month 7)	At time of permanent treatment discontinuation
Scheduling Window Days/Weeks/Months:		± 2 days	± 2 days	± 2 weeks	± 2 weeks
Administrative procedures
Informed consent	x
Informed consent for optional genetic testing (if applicable)	(x)
Informed consent for optional Cardiac‐MRI imaging (if applicable)	(x)
Inclusion criteria/Exclusion criteria	x
Treatment randomization	x
Clinical procedures/Assessments
Weight/height	x			x	x	x
Vital signs (blood pressure, pulse etc.)	x	x	x	x	x	x
Physical exam	x	x	x	x	x	x
Symptoms	x	x	x	x	x	x
Medical history	x
Family history	x
Prior and concomitant medication review	x	x	x	x	x	x
Electrocardiogram (12‐lead)	x			x	x	x
Transthoracic echocardiogram	x			x	x	x
Cardiopulmonary exercise testing	x			x	x	x
ECG holter monitoring	x			x
Blood work	x	x	x	x	x	x
Quality of life questionnaires	x			x	x	x
Adverse events monitoring	x			x	x	x
Optional genetic testing (if applicable)	(x)
Optional Cardiac‐MRI imaging for imaging sub‐study (if applicable)	(x)			(x)